RN Mobile Menu

Search form


EULAR 2015

EULAR 2015

The news from phase 3 trials of psoriatic arthritis treatments is upbeat: certolizumab pegol (Cimzia), apremilast (Otezla), and secukinumab (Cosentyx) all continue to show positive effects.


Should you immunize your patients with rheumatoid arthritis against viral infections that could pose a danger to their health?

 ©Susie Prentice/shutterstock.com

Patients with psoriatic arthritis achieve significant improvements in signs and symptoms with the interleukin-12/23 inhibitor ustekinumab (Stelara), and they maintain those gains for 2 years, according to final results from 3 major clinical trials.

©Left-Handed Photography/Shutterstock.com

A rheumatologist picks 5 studies he found particularly noteworthy at EULAR and gets right to the point about their potential clinical implications.


There’s an app in development that could make it easier -- even fun-- for young children with juvenile idiopathic arthritis to describe where and how much they hurt.


The first study to assess the effects of DMARDs or anti-TNF treatment in a real world population of patients with inflammatory arthritis shows a clinically significant improvement in work disability, productivity loss, and disease activity-- especially in those receiving TNF-α blockers.


Blisibimod, an experimental drug that inhibits autoimmune B-cell activation and survival, produced clinically important improvements in disease activity in systemic lupus erythematosus, as well as in fatigue, in a phase 2b clinical trial.


Subscribe to EULAR 2015 on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.